In other fibrotic models, the progression of NAFLD to non-alcoholic steatohepatitis and liver fibrosis has been blocked in animal models with PAT-505, another novel ATX inhibitor [180]. Here, ENPP2 is linked to metabolic dysfunction-associated steatotic liver disease.